BR112018075964A2 - preparação de derivados de fator xa - Google Patents

preparação de derivados de fator xa

Info

Publication number
BR112018075964A2
BR112018075964A2 BR112018075964-3A BR112018075964A BR112018075964A2 BR 112018075964 A2 BR112018075964 A2 BR 112018075964A2 BR 112018075964 A BR112018075964 A BR 112018075964A BR 112018075964 A2 BR112018075964 A2 BR 112018075964A2
Authority
BR
Brazil
Prior art keywords
protein
derivatives
factor
preparation
chromatograph
Prior art date
Application number
BR112018075964-3A
Other languages
English (en)
Inventor
Karbarz Mark
B. Conley Pamela
Lu Genmin
Original Assignee
Portola Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60663351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018075964(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Portola Pharmaceuticals, Inc. filed Critical Portola Pharmaceuticals, Inc.
Publication of BR112018075964A2 publication Critical patent/BR112018075964A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente revelação fornece métodos para fabricação de uma proteína derivada de fxa em larga escala, o que leva a um alto rendimento de produto de proteína altamente puro. o método pode incluir adicionar um detergente a uma amostra que contém um construto de polinucleotídeo que codifica a proteína e purificar a proteína através de um cromatógrafo de afinidade baseada em inibidor de tripsina de soja (sti), um cromatógrafo de troca de íons e modo misto e uma interação hidrofóbica.
BR112018075964-3A 2016-06-17 2017-06-19 preparação de derivados de fator xa BR112018075964A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351841P 2016-06-17 2016-06-17
US62/351,841 2016-06-17
PCT/US2017/038169 WO2017219034A2 (en) 2016-06-17 2017-06-19 Preparation of factor xa derivatives

Publications (1)

Publication Number Publication Date
BR112018075964A2 true BR112018075964A2 (pt) 2019-04-02

Family

ID=60663351

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018075964-3A BR112018075964A2 (pt) 2016-06-17 2017-06-19 preparação de derivados de fator xa

Country Status (23)

Country Link
US (4) US10604748B2 (pt)
EP (2) EP3472314B1 (pt)
JP (3) JP6959268B2 (pt)
KR (1) KR102373215B1 (pt)
CN (3) CN118271391A (pt)
AU (2) AU2017283720C1 (pt)
BR (1) BR112018075964A2 (pt)
CA (1) CA3027457A1 (pt)
CL (2) CL2018003654A1 (pt)
CO (1) CO2019000120A2 (pt)
DK (1) DK3472314T3 (pt)
EA (1) EA037815B1 (pt)
ES (1) ES2875538T3 (pt)
HU (1) HUE054597T2 (pt)
IL (1) IL263591B2 (pt)
MX (1) MX2018015873A (pt)
PE (1) PE20190661A1 (pt)
PH (1) PH12018502614A1 (pt)
PL (1) PL3472314T3 (pt)
PT (1) PT3472314T (pt)
SG (1) SG11201810915QA (pt)
SI (1) SI3472314T1 (pt)
WO (1) WO2017219034A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268783B2 (en) * 2007-09-28 2012-09-18 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same
AU2013375294B2 (en) * 2013-01-24 2018-08-09 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor Xa derivatives
CN118271391A (zh) * 2016-06-17 2024-07-02 阿雷克森制药公司 因子xa衍生物的制备
US20210371842A1 (en) * 2018-06-19 2021-12-02 Alexion Pharmaceuticals, Inc. Antidotes to factor xa inhibitors
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189019A (en) * 1990-04-23 1993-02-23 Merck & Co., Inc. Antistasin derived anticoagulant protein
US5589571A (en) 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
JPH1066572A (ja) * 1996-08-29 1998-03-10 Showa Sangyo Co Ltd 高純度の大豆トリプシンインヒビターの製造方法
US6376515B2 (en) 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
KR101358574B1 (ko) 2005-11-08 2014-02-04 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 억제제, ｎ­（5­클로로­2­피리디닐）­2­［［4­［（디메틸아미노）이미노메틸］벤조일］아미노］­5­메톡시­벤자마이드의 약제학적 염 및 다형체
BR122022001846B1 (pt) 2007-09-28 2022-12-27 Portola Pharmaceuticals, Inc. Uso de polipeptídeo de duas cadeias para preparo de medicamento para reduzir sangramento
US8268783B2 (en) 2007-09-28 2012-09-18 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same
WO2010056765A2 (en) 2008-11-14 2010-05-20 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
PT2453910T (pt) * 2009-07-15 2016-12-07 Portola Pharm Inc Formulação de dose unitária de antídoto contra inibidores de fator xa para uso na prevenção de sangramento
EP2861614B1 (en) * 2012-06-14 2016-11-30 Portola Pharmaceuticals, Inc. METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES
US20140346397A1 (en) * 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
AU2013375294B2 (en) * 2013-01-24 2018-08-09 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor Xa derivatives
MX2016003871A (es) * 2013-09-24 2016-08-04 Pfizer Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion.
ES2814157T3 (es) * 2014-08-20 2021-03-26 Portola Pharm Inc Formulaciones liofilizadas para antídoto del factor Xa
CN118271391A (zh) * 2016-06-17 2024-07-02 阿雷克森制药公司 因子xa衍生物的制备

Also Published As

Publication number Publication date
IL263591B (en) 2022-11-01
PH12018502614A1 (en) 2019-09-30
CN118271391A (zh) 2024-07-02
CL2020001733A1 (es) 2020-09-25
US20210348149A1 (en) 2021-11-11
CO2019000120A2 (es) 2019-03-29
US10954504B2 (en) 2021-03-23
US20240076642A1 (en) 2024-03-07
PT3472314T (pt) 2021-06-18
PE20190661A1 (es) 2019-05-08
ES2875538T3 (es) 2021-11-10
JP2019528242A (ja) 2019-10-10
JP2022000477A (ja) 2022-01-04
EP3926044A1 (en) 2021-12-22
SG11201810915QA (en) 2019-01-30
AU2017283720C1 (en) 2024-07-25
MX2018015873A (es) 2019-08-12
US20170369862A1 (en) 2017-12-28
JP7273918B2 (ja) 2023-05-15
WO2017219034A3 (en) 2019-03-14
EA201990052A1 (ru) 2019-05-31
AU2017283720A1 (en) 2019-01-03
AU2017283720B2 (en) 2022-11-17
KR20190019134A (ko) 2019-02-26
CA3027457A1 (en) 2017-12-21
IL263591A (en) 2019-02-03
CN110167575A (zh) 2019-08-23
EP3472314B1 (en) 2021-05-05
IL263591B2 (en) 2023-03-01
DK3472314T3 (da) 2021-07-26
PL3472314T3 (pl) 2021-11-22
EA037815B1 (ru) 2021-05-25
EP3472314A4 (en) 2020-01-22
WO2017219034A2 (en) 2017-12-21
JP6959268B2 (ja) 2021-11-02
US20200208131A1 (en) 2020-07-02
US10604748B2 (en) 2020-03-31
CN110167575B (zh) 2024-03-15
AU2023200825A1 (en) 2023-03-16
CN116425860A (zh) 2023-07-14
CL2018003654A1 (es) 2019-01-25
SI3472314T1 (sl) 2021-11-30
KR102373215B1 (ko) 2022-03-10
JP2023086970A (ja) 2023-06-22
EP3472314A2 (en) 2019-04-24
US11845966B2 (en) 2023-12-19
HUE054597T2 (hu) 2021-09-28

Similar Documents

Publication Publication Date Title
BR112018075964A2 (pt) preparação de derivados de fator xa
BR112016020517A2 (pt) método de produção de lipídeo através da utilização de ss-cetoacil-acp sintase
BR112018077358A2 (pt) tagatose-6-fosfato fosfatase termoestável inovadora e um método para produzir tagatose com o uso da mesma
GB201111594D0 (en) New improved process
BR112017018365A2 (pt) uso de lavagens alcalinas durante cromatografia para remoção de impurezas
EA201891878A1 (ru) Очистка белков
BR112017010069A2 (pt) redução seletiva de resíduos cisteína em anticorpos para il-17
MX2020000288A (es) Cromatografia.
EA201491564A1 (ru) Осаждение фракции i-iv-1 иммуноглобулинов из плазмы
BR112016028496A2 (pt) análise quantitativa de proteínas transgênicas
BR112016023680A2 (pt) ?processo de purificação de gonadotropina?
EA201892515A1 (ru) Стероидные 6,7-бета-эпоксиды в качестве интермедиатов
BR112016030604B8 (pt) Processo para preparação de ácidos 3- hidroxipicolínicos
BR112022009688A2 (pt) Processo para a síntese de (3-cloro-2-piridil)hidrazina
AR111465A1 (es) Método para la purificación de anticuerpos análogos por el uso de cromatografía de intercambio de cationes
BR112015008661A2 (pt) processos de separação para proteína de soja
WO2015068075A3 (en) Detection of tau
BR112015026306A2 (pt) método para separação e purificação da lactoferrina humana recombinante das sementes de arroz
MX2015014945A (es) Proceso de sintesis de ambrox a partir de ageratina jocotepecana.
TW201611889A (en) Solid catalyst for dehydration of sugar alcohol and method for preparing dianhydrosugar alcohol using said catalyst
BR112012027772A2 (pt) método para separação do triptofano
EA201792655A1 (ru) Способ синтеза 9,9-бис(гидроксиметил)флуорена
BR112017021401A2 (pt) produção de compostos fragrantes
NZ742210A (en) Neospora vaccine composition
BR112017016492A2 (pt) processo para a purificação de ga-68 a partir de eluato que deriva de geradores de 68ge/ 68ga e colunas cromatográficas para uso no dito processo

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]